A recent statement from Novo Nordisk's CEO sheds light on the company's perspective on the obesity drug market. According to the CEO, investors may be underestimating the demand for differentiation among obesity treatments.

The comment suggests that Novo Nordisk believes there will be room for multiple players in the market, rather than a single dominant company. This statement is in response to the competitive landscape, which includes other major pharmaceutical companies like Lilly.

Further details on Novo Nordisk's strategy and outlook can be found in the original report from Reuters, as reported in the Galveston County Daily News.